ASH 2020: AML Secondary to MDS - Updates for Patients | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

ASH 2020: AML Secondary to MDS - Updates for Patients

Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Presentation Date: 
Tue, 03/09/2021 - 12:30pm (EST)

Dr.DiNardio provides a review of the most important papers and studies presented at the 62nd American Society of Hematology Annual Meeting for patients with AML secondary to MDS.  We will have a follow up webinar with a direct focus on lower and intermediate risk MDS papers and studies. 

Courtney D. DiNardo is an Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.  Dr. DiNardo is a clinical researcher with a specialized focus on prognostication and personalized therapeutics for patients with myeloid malignancies. She has completed formal training in epidemiology and biostatistics, with a Master's of Science in Clinical Epidemiology (2012). She is the principal investigator for multiple novel therapeutic agents currently in clinical trial and was involved in the clinical development of venetoclax for myeloid malignancies.  Dr. DiNardo is an internationally recognized researcher and clinician.